NASDAQ:PGEN Precigen (PGEN) Stock Price, News & Analysis $0.94 -0.02 (-2.08%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.93▼$1.0050-Day Range$0.94▼$1.8852-Week Range$0.84▼$1.93Volume705,824 shsAverage Volume1.01 million shsMarket Capitalization$237.27 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Precigen alerts: Email Address Precigen MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside644.7% Upside$7.00 Price TargetShort InterestBearish10.72% of Float Sold ShortDividend StrengthN/ASustainability-0.77Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$50,000 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.42) to ($0.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.06 out of 5 starsMedical Sector165th out of 910 stocksPharmaceutical Preparations Industry66th out of 426 stocks 3.3 Analyst's Opinion Consensus RatingPrecigen has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoveragePrecigen has only been the subject of 2 research reports in the past 90 days.Read more about Precigen's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.72% of the float of Precigen has been sold short.Short Interest Ratio / Days to CoverPrecigen has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.Change versus previous monthShort interest in Precigen has recently decreased by 5.20%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPrecigen does not currently pay a dividend.Dividend GrowthPrecigen does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePrecigen has received a 75.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Precigen is -0.77. Previous Next 1.8 News and Social Media Coverage News SentimentPrecigen has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Precigen this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for PGEN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Precigen to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Precigen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $50,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders44.90% of the stock of Precigen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 33.51% of the stock of Precigen is held by institutions.Read more about Precigen's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Precigen are expected to grow in the coming year, from ($0.42) to ($0.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Precigen is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Precigen is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrecigen has a P/B Ratio of 5.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Precigen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Gold RepublicChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . Click here now to get your free 'De-Dollarization' Guide. About Precigen Stock (NASDAQ:PGEN)Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.Read More PGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PGEN Stock News HeadlinesAugust 14, 2024 | insidertrades.comPrecigen, Inc. (NASDAQ:PGEN) SVP Acquires $49,999.55 in StockSeptember 5 at 4:55 AM | americanbankingnews.comPrecigen (NASDAQ:PGEN) Share Price Passes Below 200-Day Moving Average of $1.44September 7, 2024 | Paradigm Press (Ad)Ex-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…August 30, 2024 | 247wallst.com3 Penny Stocks to Buy With $500August 28, 2024 | americanbankingnews.comBrokerages Set Precigen, Inc. (NASDAQ:PGEN) Price Target at $7.00August 28, 2024 | americanbankingnews.comPrecigen, Inc. (NASDAQ:PGEN) Receives Consensus Rating of "Moderate Buy" from AnalystsAugust 17, 2024 | finance.yahoo.comPrecigen Second Quarter 2024 Earnings: Misses ExpectationsAugust 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Precigen Amid Promising PRGN-2012 Clinical Data and Strategic FocusSeptember 7, 2024 | Paradigm Press (Ad)Ex-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…August 15, 2024 | msn.comPrecigen, Inc. (NASDAQ:PGEN) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | finanznachrichten.dePrecigen, Inc.: Precigen Reports Second Quarter and First Half 2024 Financial Results and Business UpdatesAugust 15, 2024 | msn.comWhy Lumentum Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving PremarketAugust 15, 2024 | markets.businessinsider.comPGEN Stock Earnings: Precigen Misses EPS, Misses Revenue for Q2 2024August 14, 2024 | prnewswire.comPrecigen Reports Second Quarter and First Half 2024 Financial Results and Business UpdatesAugust 14, 2024 | markets.businessinsider.comPrecigen earnings: here's what Wall Street expectsAugust 11, 2024 | nasdaq.comWeekly Review: ANTX Downsizes, ALDX Aces Dry Eye Disease Trial, FDA Oks 1st Epinephrine Nasal SprayAugust 9, 2024 | prnewswire.comPrecigen to Announce Second Quarter and First Half 2024 Financial Results on August 14thAugust 7, 2024 | prnewswire.comPrecigen Announces Pricing of $30.0 Million Public Offering of Common StockSee More Headlines Receive PGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Precigen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PGEN CUSIPN/A CIK1356090 Webwww.precigen.com Phone(301) 556-9900FaxN/AEmployees202Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$10.00 Low Stock Price Target$4.00 Potential Upside/Downside+644.7%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-95,900,000.00 Net Margins-3,084.55% Pretax Margin-3,131.40% Return on Equity-90.99% Return on Assets-67.26% Debt Debt-to-Equity RatioN/A Current Ratio1.03 Quick Ratio1.03 Sales & Book Value Annual Sales$4.39 million Price / Sales54.06 Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book5.53Miscellaneous Outstanding Shares252,420,000Free Float139,083,000Market Cap$237.27 million OptionableOptionable Beta1.67 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Randal J. Kirk J.D. (Age 71)Executive Chairman Comp: $100kDr. Helen Sabzevari MPH (Age 62)Ph.D., President, CEO & Director Comp: $1.02MMr. Harry Thomasian Jr. (Age 62)Chief Financial Officer Comp: $508.54kMr. Rutul R. Shah (Age 43)Chief Operating Officer Comp: $453.02kMr. Donald P. Lehr J.D. (Age 49)Ph.D., Chief Legal Officer & Corporate Secretary Comp: $618.32kMr. Jeffrey Thomas Perez J.D. (Age 52)Senior Vice President of Intellectual Property Affairs Comp: $540.67kMr. Steven HarasymVP & Head of Investor RelationsMr. Rob RussellVP & Head of Human ResourcesDr. Douglas E. Brough Ph.D. (Age 69)Senior VP & Head of Research Dr. Bryan T. Butman Ph.D. (Age 71)Senior VP & Head of CMC More ExecutivesKey CompetitorsCellectisNASDAQ:CLLSLuna InnovationsNASDAQ:LUNAPieris PharmaceuticalsNASDAQ:PIRSBioanalytical SystemsNASDAQ:BASIEnliven TherapeuticsNASDAQ:ELVNView All CompetitorsInsiders & InstitutionsThe Manufacturers Life Insurance Company Bought 16,486 shares on 8/15/2024Ownership: 0.023%AQR Capital Management LLCBought 18,097 shares on 8/15/2024Ownership: 0.020%Renaissance Technologies LLCBought 130,500 shares on 8/9/2024Ownership: 0.469%Jeffrey Thomas PerezBought 58,823 shares on 8/9/2024Total: $49,999.55 ($0.85/share)Fore Capital LLCSold 99,980 shares on 8/8/2024Ownership: 0.082%View All Insider TransactionsView All Institutional Transactions PGEN Stock Analysis - Frequently Asked Questions How have PGEN shares performed this year? Precigen's stock was trading at $1.34 at the beginning of the year. Since then, PGEN stock has decreased by 29.9% and is now trading at $0.94. View the best growth stocks for 2024 here. How were Precigen's earnings last quarter? Precigen, Inc. (NASDAQ:PGEN) released its quarterly earnings data on Wednesday, August, 14th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. The biotechnology company had revenue of $0.72 million for the quarter, compared to analysts' expectations of $1.28 million. Precigen had a negative trailing twelve-month return on equity of 90.99% and a negative net margin of 3,084.55%. Who are Precigen's major shareholders? Precigen's top institutional shareholders include Iridian Asset Management LLC CT (0.82%), Renaissance Technologies LLC (0.47%), Sanders Morris Harris LLC (0.22%) and ClariVest Asset Management LLC (0.19%). Insiders that own company stock include Helen Sabzevari, Randal J Kirk, Steven Frank, Jeffrey Thomas Perez, Donald P Lehr, Dean J Mitchell, Jeffrey B Kindler, Harry Jr Thomasian, Rutul R Shah and Trading SA Ares. View institutional ownership trends. How do I buy shares of Precigen? Shares of PGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Precigen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Precigen investors own include ZIOPHARM Oncology (ZIOP), Nordic American Tankers (NAT), Hess (HES), Boeing (BA), OPKO Health (OPK), Celldex Therapeutics (CLDX) and TherapeuticsMD (TXMD). This page (NASDAQ:PGEN) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precigen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PGEN Stock Alerts